Justin Chen Li, CEO of Helio Genomics, sits down with Nasdaq’s Kristina Ayanian to discuss how the AI-driven healthcare company is on a mission to save lives by developing technology that can detect cancer early from a simple blood draw.
Recorded live from the Nasdaq MarketSite in Times Square, this conversation is a candid introduction to the company behind HelioLiver — and to the people working to make early cancer detection something every patient can actually reach.
Li explains why Helio Genomics chose to begin with the liver, where cancer is still caught far too late, and how pairing next-generation sequencing with artificial intelligence lets a single blood draw surface signals that traditional screening often misses. He also lays out the bigger vision: a future where checking for cancer is as routine, and as painless, as any other blood test at an annual physical.
What the conversation covers
- Why Helio Genomics built its first test around liver cancer
- How AI and blood-based diagnostics work together to flag cancer earlier
- What earlier detection means for patients — and for the cost of care
- Where the company is headed beyond the liver